azn201304236k.htm
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of April 2013

 
Commission File Number: 001-11960

 
AstraZeneca PLC
 
 
2 Kingdom Street, London W2 6BD
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X      Form 40-F __
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______           
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
 
Yes __     No X
 
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 



 
AstraZeneca PLC First Quarter Results 2013
 
 
Tomorrow, Thursday, 25 April 2013, AstraZeneca will release first quarter results 2013 at 07:00bst.
 
An analysts presentation of the first quarter results will take place at 12:00 bstand will be accessible by:
 
Teleconference with Q&A.  Dial in numbers:
 
UK (freephone): 0800 694 2370  
International:      +44 (0) 1452 557 749    
Sweden (freephone):       0200 883 079
US (freephone):  1 866 977 7645
 
Conference ID:  33804527
 
Details of the teleconference and webcast replay facilities are available on the Investor Relations section of the AstraZeneca website http://www.astrazeneca.com/financial-results and the AstraZeneca Events website: http://info.astrazenecaevents.com.
 
 
 
 

 


  
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
Date: 24 April 2013
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary